期刊文献+

apoAⅠ启动子-93 bp~-63 bp片段及-75 bp位点突变对基因转录调控作用的研究

The Role of Oligonucleotides -93~-63 bp of ApoA-Ⅰ Promoter and -75 Mutant on Gene Transcription Regulation
下载PDF
导出
摘要 目的:研究载脂蛋白AⅠ(apoAⅠ)启动子区域-93bp~-63bp对基因转录活性的影响,探讨-75bp位点G→A置换在基因转录中的作用。方法:在人类基因组数据库中截取并下载apoAⅠ基因启动子序列,对照基因图谱人工合成apoAⅠ启动子区域-93bp~-63bp片段,-75bp位点分别为突变型(A)或野生型(G),进行生物素标记。培养HepG2细胞,提取核蛋白混合物。将核蛋白与标记好的两条DNA链结合,进行电泳迁移率(EMSA)实验,观察两者结合情况。结果:apoAⅠ启动子-93bp~-63bp区域可与某种特异性核蛋白转录因子结合。-75bp位点为G等位基因的探针与含A的探针相比,核蛋白的结合明显增多。同时,竞争抑制实验表明,含G的探针与核蛋白的亲和力高于含A的探针。结论:apoAⅠ基因启动子-93bp~-63bp区域通过与核蛋白转录因子的结合参与基因调控,-75bp位点G→A置换降低与转录因子的亲和力,降低apoAI转录活性从而影响基因表达。 Objective: To study the effects of oligonucleotides -93 bp--63 bp of apoA- Ⅰ promoter and -75 bp mutant on gene transcription regulation, and to explore the effects of nuclear proteins that bind to the -75 region of apoA I promoter on gene transcription. Methods: Nuclear proteins were prepared from HepG2 cells and challenged with two labeled oligonucleotides corresponding to the region -93 bp and -63 bp from the transcription start site of apoA Ⅰ gene in the A or G configuration. Results: DNA-protein complexes were formed by two DNA oligonucleotides with nuclear proteins from HepG2 cells. Three retarded bands were visible. Competition with the homologous oligonucleotide efficiently reduced the intensity of such complexes. When oligonucleotide A was used as competitor versus labeled oligonucleotide G, unlabeled oligonucleotide G competed more efficiently than oligonucleotide A. Conclusion: The nuclear factor could mediate the activation of transcription of promoters observed in the experiment. The G→A transition decreases its binding affinity to the -75 position and represses the apoAI gene transcription.
机构地区 天津市胸科医院
出处 《天津医药》 CAS 北大核心 2006年第9期593-595,共3页 Tianjin Medical Journal
基金 天津市科技发展计划项目(项目编号:05YFSZSF02700)
关键词 载脂蛋白A-Ⅰ 基因 转录 遗传 启动区(遗传学) apolipoprotein A- Ⅰ gene transcription, genetic promoter regions (genetics)
  • 相关文献

参考文献12

  • 1Guinchard-Foulon E,Rodriguez-Lafrasse C,Rousson R,et al.HDL-cholesterol:role of its dosage in the assessment of cardiovascular risk.Ann Biol Clin,2003,61:549-556
  • 2Su YR,Ishiguro H,Major AS,et al.Macrophage apolipoprotein A-Ⅰ expression protects against atherosclerosis in ApoE-deficient mice and up-regulates ABC transporters.Mol Ther,2003,8:576-583
  • 3Bai H,Saku K,Liu R,et al.Analysis of a new polymorphism in the human apolipoprotein A-Ⅰ gene:Association with serum lipoprotein levels and coronary heart disease.J Cardiol,1996,28(4):207-212
  • 4Zhang B,Bai H,Liu R,et al.Serum high-density lipoprotein-cholesterol levels modify the association between plasma levels of oxidatively modified low-density lipoprotein and coronary artery disease in men.Metabolism,2004,53:423-429
  • 5Zhao XQ,Morse JS,Dowdy AA,et al.Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).Am J Cardiol,2004,93(3):307-312
  • 6Sorci-Thomas MG,Thomas MJ.The effects of altered apolipoprotein A-Ⅰ structure on plasma HDL concentration.Trends Cardiovasc Med,2002,12:121-128
  • 7Su YR,Ishiguro H,Major AS,et al.Macrophage apolipoprotein A-Ⅰ expression protects against atherosclerosis in ApoE-deficient mice and up-regulates ABC transporters.Mol Ther,2003,8:576-583
  • 8Braschi S,Neville TA,Vohl MC,et al.Apolipoprotein A-Ⅰ charge and conformation regulate the clearance of reconstituted high density lipoprotein in vivo.J Lipid Res,1999,40:522-532
  • 9Lamarche B,Uffelman KD,Carpentier A,et al.Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apoA-Ⅰ in heathy men.J Clin Invest,1999,103:1191-1199
  • 10Elvira A,Evelina M,Francesco C,et al.A polymophism (G-A Transition) in the -78 position of the apolipoprotein A-Ⅰ promoter increase transcription efficiency.J Biol Chem,1994,269:17371-17374

二级参考文献9

  • 1Bai H, Saku K, Liu R, et al. Analysis of a new polymorphism in the human apolipoprotein A-I gene: Association with serum lipoprotein levels and coronary heart disease. J Cardiol, 1996,28: 207- 215.
  • 2Paul-Hayase H, Rosseneu M, Robinson D, et al. Polyrnorphisms in the apolipoprotein(apo) AI-C Ⅲ- AIV gene cluster: Detection of genetic variation determining plasma apoAI, aopC Ⅲ and apo A Ⅳ concentration. Hum Genet, 1992, 88:439- 446.
  • 3Duverger N, Kruth H, Emmanue L, et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipop roteinA-I-transgenic rabbits. Circulation, 1996, 94; 713 - 717.
  • 4Patrick B, Florence EJ ,Jean MC, et al. Somatic gene tansfer of human apo AI inhibits atherosclerosis in mouse models. Circulation, 1999, 99:105 - 110.
  • 5Smith JD, Brinton EA, Breslow, et al.Polymorphism in the human apolipoprotein AI gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in vitro. J Clin Invest, 1992, 89:1796 - 800.
  • 6Wilson PW, Anderson KN, Harris T, et al.Determinants of change in total cholesterol and HDL-C with age: the Framingham study. J Gerontol, 1994, 49 : M252 - 257.
  • 7Wang XL, Badenhop R, Humphrey KE, et al. New Mspl polymorphism at + 83 bp of the human apolipoprotein AI gene:association with increased circulating high density lipoprotein cholesterol levels. Genet Epodemiol, 1996, 13(1) : 1 - 6.
  • 8Pulkkinen A, Viitanen L, Kareinen A, et al. MspI polymorphism at + 83 bp in intron 1 of the human apolipoprotein AI gene is associated with elevated levels of HDL cholesterol and apolipoprotein AI in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease. Diabetes Care,2000,23(6):791-798.
  • 9Heng CK, Low PS, Saha N. Variations in the promoter region of the apolipoprotein A-I gene influence plasma lipoprotein(a) levels in Asian indian neonates from Singapore. Pediatric Res,2001,49:514 - 518.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部